{"id":30003,"date":"2022-08-31T10:52:17","date_gmt":"2022-08-31T05:52:17","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=97253"},"modified":"2022-08-31T10:52:17","modified_gmt":"2022-08-31T05:52:17","slug":"junshi-biosciences-announces-2022-interim-financial-results-and-provides-corporate-updates","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-2022-interim-financial-results-and-provides-corporate-updates\/","title":{"rendered":"Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates"},"content":{"rendered":"
— Clinical trials of core drug candidates are progressing steadily with the debut of the company\u2019s FIH asset<\/em><\/p>\n — Toripalimab\u2019s sales performance is consistently improving; the US BLA is under review<\/em><\/p>\n SHANGHAI, China, Aug. 31, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced its 2022 interim financial results and provided corporate updates.<\/p>\n FINANCIAL HIGHLIGHTS<\/strong><\/p>\n BUSINESS HIGHLIGHTS<\/strong><\/p>\n During the first half of 2022, Junshi Biosciences focused on \u201cunmet clinical needs\u201d and made original, unprecedented and breakthrough progress in the discovery, R&D, production and commercialization of innovative drugs and therapies, which have filled various gaps in China and are leading in related fields globally. The following achievements and milestones were attained:<\/p>\n About Junshi Biosciences<\/strong> In the face of the pandemic, Junshi Biosciences\u2019 response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the\u00a0Institute of Microbiology of the Chinese Academy\u00a0of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. A Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 versus nirmatrelvir\/ritonavir (\u201cPAXLOVID\u201d) for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 provided patients with a shorter median time to sustained clinical recovery, while achieving statistical superiority. The JS016 and VV116 programs are a part of the company\u2019s continuous innovation for disease control and prevention of the global pandemic.<\/p>\n Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http:\/\/junshipharma.com<\/a>.<\/p>\n Junshi Biosciences Contact Information<\/strong>\n
\n
\n
\n
\nFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib\/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in\u00a0China\u00a0to be approved for clinical trials by the NMPA.<\/p>\n
\nIR Team:
\nJunshi Biosciences
\ninfo@junshipharma.com<\/a>
\n+ 86 021-6105 8800<\/p>\n